Get the Stockscreener App
11.85
0.85%
0.10
After Hours:
11.85
Roivant Sciences Ltd stock is traded at $11.85, with a volume of 3.48M.
It is up +0.85% in the last 24 hours and up +4.31% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.75
Open:
$11.75
24h Volume:
3.48M
Relative Volume:
0.61
Market Cap:
$8.09B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
2.0973
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+3.13%
1M Performance:
+4.31%
6M Performance:
+12.22%
1Y Performance:
+4.77%
1-Day Range:
$11.68
$11.91
1-Week Range:
$10.90
$12.12
52-Week Range:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.85 | 8.02B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant’s High-Stakes Pipeline Bets On Biotech Breakthroughs - Finimize
Roivant plans $500M new share repurchase as brepocitinib data readout nears - MSN
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. Approaches Psychological Resistance Level2025 Big Picture & Weekly Market Pulse Alerts - 선데이타임즈
Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Just Slashed This Year's Revenue Estimates By 17% - 富途牛牛
Roivant Sciences’ (ROIV) Aggressive Buybacks Amid Losses: Commitment to Shareholders or Growth Uncertainty? - simplywall.st
Roivant Sciences Earnings Call: Progress Amid Challenges - TipRanks
Why Roivant Sciences Stock Bounced Back on Tuesday - Mitrade
Roivant Sciences shares rise 2.91% intraday after announcing a $500 million share repurchase program. - AInvest
Chairman on Gubra CEO change: Henrik Blou wants to try something different - medwatch.com
Leerink Partners raises Roivant Sciences stock price target to $18 on lower share count By Investing.com - Investing.com South Africa
Leerink Partners raises Roivant Sciences stock price target to $18 on lower share count - Investing.com Australia
Roivant Sciences Q1 2025 Earnings Call Highlights: Strong Cash Position and Share Repurchase Amidst Legal and Market Challenges - AInvest
Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Why Roivant Sciences Ltd. stock attracts strong analyst attentionHyper-Growth Screener - classian.co.kr
Roivant Sciences Reports Q1 2025 Financial Results - TipRanks
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update - GlobeNewswire
Why Roivant Sciences Stock Was Slipping on Monday - Mitrade
Roivant Sciences Sees Losses Grow But Investors Hold Steady - Finimize
Roivant Sciences Q1 2026 Earnings Call Transcript - MarketBeat
Roivant Deepens Its Losses But Keeps Investors On Board - Finimize
Roivant Sciences Reports Q1 EPS of 33c, Revenue of $2.17M, and Initiates $1.5B Share Buyback Program - AInvest
A Glimpse of Roivant Sciences's Earnings Potential - 富途牛牛
Roivant Sciences Ltd. announces an Equity Buyback for $500 million worth of its shares. - MarketScreener
Roivant Sciences Completes Equity Buyback Plan with 19.59% of Shares Repurchased - AInvest
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024. - MarketScreener
Roivant's Q1 2025 Earnings Call: Unraveling the Contradictions in Brepo's DM Market Positioning and Efficacy Expectations - AInvest
Roivant Sciences Ltd. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Roivant Sciences Ltd., Q1 2026 Earnings Call, Aug 11, 2025 - MarketScreener
Roivant Sciences Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2025 - MarketScreener
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Roivant Sciences earnings missed by $0.08, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences Q1 Swings to Loss, Revenue Falls - MarketScreener
Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln - MarketScreener
Roivant Sciences Ltd. (ROIV) Misses Q1 EPS by 8c - StreetInsider
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q1 Revenue $2.2M, vs. FactSet Est of $7.3M - MarketScreener
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q1 Net Loss $0.33 a Share, vs. FactSet Est of $0.28 Loss - MarketScreener
Will Roivant Sciences Ltd. outperform the marketAI Intraday Market Movement Prediction Tool - Newser
Will Roivant Sciences Ltd. see short term momentumStrong Buy Signal Summary with Entry Zone - Newser
How high can Roivant Sciences Ltd. stock goDaily Entry Opportunity Forecasting Tool - Newser
Is Roivant Sciences Ltd. stock a good hedge against inflationTechnical Reversal Pattern Summary and Tracker - Newser
Roivant Sciences Earnings Expectations: A Closer Look at the Company's Performance and Analyst Sentiments - AInvest
Roivant Sciences (ROIV) to Release Earnings on Monday - Defense World
What makes Roivant Sciences Ltd. stock price move sharplyChart Driven Opportunity Scanner with Alerts - Newser
Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday - Investing.com Australia
Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday By Investing.com - Investing.com South Africa
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):